secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0000950170-24-058629
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon Q1 net loss $25.2M; cash $264.9M; Phase 3 GBS data due Q2 2024
----------------------------------------------------------------------

- Net loss $25.2M ($0.21/share) vs $38.7M ($0.52) in Q1 2023; R&D spend $21M vs $32.3M.
- Cash, equivalents & short-term investments $264.9M as of March 31, 2024, runway into mid-2026.
- Topline Phase 3 data for ANX005 in Guillain-Barré Syndrome expected Q2 2024.
- Pivotal Phase 3 ARCHER II trial for ANX007 in geographic atrophy to start mid-2024; ARROW head-to-head vs SYFOVRE planned H2 2024.
- Proof-of-concept data for oral ANX1502 in cold agglutinin disease on track for H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000095017024058629/0000950170-24-058629-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000095017024058629/annx-20240513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-058629

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer